百时美施贵宝重获RayzeBio管线产品在大中华区市场独家开发和商业化权利

界面
20 Dec 2024

12月19日,百时美施贵宝宣布,公司已与艾博兹医药达成了一项协议,百时美施贵宝重新取得了在大中华区开发和商业化ABZ-706(相当于RYZ801)的独家权利,该管线产品用于针对GPC3靶点的肝细胞癌治疗,同时也终止了与艾博兹之前签订的一项广泛授权协议,该协议授予艾博兹对RayzeBio至多四个管线产品(包括ABZ-706)在这些市场的开发和商业化权利。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10